Agencies | Governor
Virginia Regulatory Town Hall
Agency
Department of Health Professions
Board
Board of Pharmacy
chapter
Regulations Governing the Practice of Pharmacy [18 VAC 110 ‑ 20]
Previous Comment     Next Comment     Back to List of Comments
4/10/21  8:05 pm
Commenter: Leslie DuVal

CDC Guidelines
 

Current CDC guidelines for opioid prescribing are:

Acute pain-"Clinicians should prescribe the lowest effective dose of immediate release opioid and no greater quantity than needed for the expected duration of pain severe enough to require opioids. Three days or less is often sufficient; more than 7 days is rarely needed" (cdc.gov).

Chronic pain- "Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic use or of dose escalation. Clinicians should evaluate benefits and harm of continued therapy with patients every 3 months or more frequently. If benefits do not outweigh the harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower doses or to taper and discontinue opioids"(cdc.gov).

Current VA law states:

"A prescription for a Schedule II drug shall be dispensed in good faith but in no case shall it be dispensed more than six months after the date on which the prescription was issued"(18VAC110-20-290, law.lis.virginia.gov).

Decreasing the length of time during which an opioid prescription is viable for dispensing will more effectively align VA law with the CDC guidelines, and reinforce the current Virginia laws regarding treatment with opioids. This change will hold all parties more accountable for responsible opioid use.

Regarding acute prescriptions: the intention of any acute treatment is immediate mitigation or resolution. The CDC guidelines state that opioid prescriptions for acute conditions "should be for a quantity no more than the expected duration of pain severe enough to require opioids", and more than a 7 day supply is rarely required. Additionally, Virginia law currently states that "a prescriber providing treatment for acute pain shall not prescribe a controlled substance containing an opioid in a quantity that exceeds a 7 day supply as determined by the manufacturer's directions for use, unless extenuating circumstances are clearly documented in the medical record" (18VAC85-21-40, law.lis.virginia.gov). It therefore logically follows that a prescription issued for an acute condition should be filled immediately and a 7 day window from the date written is a reasonable time frame during which said prescription should be dispensed. Beyond 7 days the pain should either be at a level controllable by non-opioid measures, or the patient should be re-evaluated. 

Regarding chronic prescriptions: the CDC guidelines state that (stable) patients should be re-evaluated at a minimum of every 3 months. Additionally, current Virginia law states that prescribers treating chronic pain "shall document the rationale to continue opioid therapy every 3 months" (18VAC85-21-70, law.lis.virginia.gov). It therefore is a reasonable expectation that a prescription issued for a chronic condition should be dispensed within 3 months from the date written. 

Both scenarios support the argument that opioid prescriptions should be viable for less than 6 months. Additionally, opioid prescriptions are required to be electronically issued (54.1-3408.02, law.lis.virginia.gov), which affords clinicians tighter control over prescribing, determines where the opioid is dispensed, and allows greater visibility of patient compliance. This further upholds the recommendation of curtailing the expiration date of opioid prescriptions. The opioid epidemic continues. The intention of this petition is to block unnecessary dispensing of potentially therapeutically irrelevant opioids. I earnestly ask that this Board actively considers this petition.

References

cdc.gov. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.MMWR. (www.cdc.gov/mmwr).

Administrative Code of Virginia. (law.lis.virginia.gov).

 

 

 

CommentID: 97700